-
Publication Venue For
-
En Bloc Resection of Bladder Tumors: Style or Substance?.
78:570-571.
2020
-
National Quality Improvement Program in Transurethral Resection of Bladder Tumor: A Model for the Rest of Us, Even if We Cannot Share All Results..
78:531-532.
2020
-
A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry..
78:316-320.
2020
-
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial..
78:347-357.
2020
-
From Dog's Breakfast to Michelin Guide: Post-bacillus Calmette-Guérin Trials in Non-muscle-invasive Bladder Cancer..
78:400-401.
2020
-
Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus..
78:371-378.
2020
-
Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality Dess RT, Hartman HE, Mahal BA, et al JAMA Oncol 2019;5:975-83..
77:129-130.
2020
-
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer..
76:562-571.
2019
-
RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression..
76:157-166.
2019
-
Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review..
75:464-476.
2019
-
Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes..
74:720-721.
2018
-
Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma..
74:842-843.
2018
-
Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer..
74:526.
2018
-
Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy..
74:234-235.
2018
-
Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer..
74:99-106.
2018
-
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017..
73:178-211.
2018
-
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results..
73:62-68.
2018
-
Balancing Risks in Prostate-specific Antigen Recurrence: The Fox Versus the Hedgehog..
72:918-919.
2017
-
RECISTing the Temptation to Prematurely Stop Nivolumab..
72:377-378.
2017
-
Need for Evidence and Consensus on Laser Treatment for Management of Select Primary Penile Tumors..
72:4-6.
2017
-
Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma..
71:79-80.
2017
-
New and Established Technology in Focal Ablation of the Prostate: A Systematic Review..
71:17-34.
2017
-
Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer..
70:714-717.
2016
-
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer..
70:675-683.
2016
-
Percutaneous Nephrolithotomy: Update, Trends, and Future Directions..
70:382-396.
2016
-
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel..
69:980-983.
2016
-
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?.
69:231-244.
2016
-
Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results..
69:116-128.
2016
-
Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach..
68:891-898.
2015
-
A systematic review of hypofractionation for primary management of prostate cancer..
68:683-691.
2015
-
Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas..
68:77-83.
2015
-
Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting..
67:771-777.
2015
-
Burden of disease matters when it comes to systemic therapy for prostate cancer..
67:448-450.
2015
-
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort..
67:310-318.
2015
-
Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment?.
67:210-211.
2015
-
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer..
67:100-110.
2015
-
Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity..
67:85-97.
2015
-
Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer..
65:852-855.
2014
-
Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?.
65:873-874.
2014
-
New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?.
65:300-302.
2014
-
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer..
65:3-6.
2014
-
Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility..
64:394-396.
2013
-
Novel immunotherapeutic strategies in development for renal cell carcinoma..
63:881-889.
2013
-
New and emerging therapies for bone metastases in genitourinary cancers..
63:309-320.
2013
-
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings..
63:58-66.
2013
-
Rationale for percutaneous biopsy and histologic characterisation of renal tumours..
62:491-504.
2012
-
Objective evaluation of bone metastases in prostate cancer: to what end?.
62:85-87.
2012
-
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes..
61:664-675.
2012
-
Contemporary management of ureteral stones..
61:764-772.
2012
-
Vesicoureteral reflux: current trends in diagnosis, screening, and treatment..
61:773-782.
2012
-
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer..
61:549-559.
2012
-
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy..
61:443-451.
2012
-
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer..
61:363-369.
2012
-
Baseline prostate-specific antigen testing at a young age..
61:1-7.
2012
-
Treatment of localised renal cell carcinoma..
60:662-672.
2011
-
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review..
60:81-93.
2011
-
Contemporary management of postprostatectomy incontinence..
59:985-996.
2011
-
Complications of laparoscopic and percutaneous renal cryoablation in a single tertiary referral center..
58:142-147.
2010
-
Focal therapy for prostate cancer: possibilities and limitations..
58:57-64.
2010
-
Predicting occult multifocality of renal cell carcinoma..
58:118-126.
2010
-
Keeping an Open Mind About Novel Concepts for Management of Prostate Cancer..
68:937-938.
2015
-
Words of wisdom. Re: Tracking the clonal origin of lethal prostate cancer..
66:390-391.
2014
-
Targeted prostate biopsies: the complexity behind a simple concept..
66:30-31.
2014
-
Will the future of health care lead to the end of the robotic golden years?.
65:325-327.
2014
-
Maintenance bacillus Calmette-Guérin: why is there continued debate?.
64:586-587.
2013
-
Interpreting a study on bladder cancer screening..
64:48-50.
2013
-
Words of wisdom. Re: final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance..
64:171-172.
2013
-
When should we pull the trigger for post-radical prostatectomy radiotherapy?.
62:488-490.
2012
-
Open versus laparoscopic nephroureterectomy: is there really a debate?.
61:722-723.
2012
-
Is tumor response important for renal carcinoma?.
59:16-17.
2011
-
Corrigendum to "Focal Therapy for Prostate Cancer: Possibilities and Limitations" [Eur Urol 2010;58:57-64]..
58:644.
2010
-
Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts..
57:452.
2010
-
Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example..
55:1266-1268.
2009
-
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
2017